radiopharmaceuticals

Summary

Summary: Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161)

Top Publications

  1. ncbi Recommendations on the use of 18F-FDG PET in oncology
    James W Fletcher
    Department of Radiology, Indiana Purdue University, Indiana University School of Medicine, Indianapolis, Indiana 46202 5253, USA
    J Nucl Med 49:480-508. 2008
  2. pmc From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors
    Richard L Wahl
    Division of Nuclear Medicine, Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 0817, USA
    J Nucl Med 50:122S-50S. 2009
  3. pmc FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0
    Ronald Boellaard
    Department of Nuclear Medicine and PET Research, VU University Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 37:181-200. 2010
  4. ncbi Impact of animal handling on the results of 18F-FDG PET studies in mice
    Barbara J Fueger
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    J Nucl Med 47:999-1006. 2006
  5. doi Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT
    Damian Wild
    Clinic and Institute of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
    J Nucl Med 51:1059-67. 2010
  6. ncbi Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
    Malik E Juweid
    Department of Radiology, University of Iowa, Iowa City, IA 52242, USA
    J Clin Oncol 25:571-8. 2007
  7. ncbi [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease
    M A Mintun
    Department of Radiology, Washington University School of Medicine, St Louis, MO 63110, USA
    Neurology 67:446-52. 2006
  8. ncbi Consensus nomenclature for in vivo imaging of reversibly binding radioligands
    Robert B Innis
    National Institute of Mental Health, Molecular Imaging Branch, Bethesda, Maryland, USA
    J Cereb Blood Flow Metab 27:1533-9. 2007
  9. pmc Toward optimization of imaging system and lymphatic tracer for near-infrared fluorescent sentinel lymph node mapping in breast cancer
    J Sven D Mieog
    Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands
    Ann Surg Oncol 18:2483-91. 2011
  10. ncbi Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate
    Roelf Valkema
    Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    J Nucl Med 46:83S-91S. 2005

Research Grants

  1. MIBG ANALOGUE RADIOPHARMACEUTICALS
    Ganesan Vaidyanathan; Fiscal Year: 2001
  2. Ultrasound Ablation on Bone Cancer Under CT Fluoroscopy
    Everette C Burdette; Fiscal Year: 2010
  3. RECEPTOR-TARGETED COPPER RADIOPHARMACEUTICALS FOR CANCER IMAGING AND THERAPY
    Carolyn Anderson; Fiscal Year: 2009
  4. RECEPTOR-TARGETED COPPER RADIOPHARMACEUTICALS FOR CANCER IMAGING AND THERAPY
    Carolyn J Anderson; Fiscal Year: 2010
  5. Development of Novel Fluorinated Amino Acids
    Mark Goodman; Fiscal Year: 2003
  6. Development of Novel Fluorinated Amino Acids
    Mark Goodman; Fiscal Year: 2004
  7. RADIOPHARMACEUTICALS FOR BREAST TUMOR IMAGING & THERAPY
    John Katzenellenbogen; Fiscal Year: 2006
  8. RADIOPHARMACEUTICALS FOR BREAST TUMOR IMAGING & THERAPY
    John Katzenellenbogen; Fiscal Year: 2005
  9. RADIOPHARMACEUTICALS FOR BREAST TUMOR IMAGING & THERAPY
    John Katzenellenbogen; Fiscal Year: 2000
  10. RADIOPHARMACEUTICALS FOR BREAST TUMOR IMAGING & THERAPY
    John Katzenellenbogen; Fiscal Year: 2003

Detail Information

Publications286 found, 100 shown here

  1. ncbi Recommendations on the use of 18F-FDG PET in oncology
    James W Fletcher
    Department of Radiology, Indiana Purdue University, Indiana University School of Medicine, Indianapolis, Indiana 46202 5253, USA
    J Nucl Med 49:480-508. 2008
    ..Outcomes of interest included the use of (18)F-FDG PET for diagnosing, staging, and detecting the recurrence or progression of cancer...
  2. pmc From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors
    Richard L Wahl
    Division of Nuclear Medicine, Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 0817, USA
    J Nucl Med 50:122S-50S. 2009
    ..1. This article also reviews qualitative and quantitative approaches to metabolic tumor response assessment with (18)F-FDG PET and proposes a draft framework for PET Response Criteria in Solid Tumors (PERCIST), version 1.0...
  3. pmc FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0
    Ronald Boellaard
    Department of Nuclear Medicine and PET Research, VU University Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 37:181-200. 2010
    ....
  4. ncbi Impact of animal handling on the results of 18F-FDG PET studies in mice
    Barbara J Fueger
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    J Nucl Med 47:999-1006. 2006
    ..The aim of this study was to determine how these factors affect assessment of tumor glucose use by (18)F-FDG PET and to develop an imaging protocol that optimizes visualization of tumor xenografts...
  5. doi Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT
    Damian Wild
    Clinic and Institute of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
    J Nucl Med 51:1059-67. 2010
    ..The aim of this study was the preclinical evaluation of [Lys(40)(Ahx-DOTA-(68)Ga)NH(2)]-exendin-4 for PET/CT and [Lys(40)(Ahx-hydrazinonicotinamide [HYNIC]-(99m)Tc)NH(2)]-exendin-4 for SPECT/CT...
  6. ncbi Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
    Malik E Juweid
    Department of Radiology, University of Iowa, Iowa City, IA 52242, USA
    J Clin Oncol 25:571-8. 2007
    ..To develop guidelines for performing and interpreting positron emission tomography (PET) imaging for treatment assessment in patients with lymphoma both in clinical practice and in clinical trials...
  7. ncbi [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease
    M A Mintun
    Department of Radiology, Washington University School of Medicine, St Louis, MO 63110, USA
    Neurology 67:446-52. 2006
    ..The authors used this imaging technique to investigate whether abnormal binding occurs in clinically normal individuals, prior to the development of cognitive changes...
  8. ncbi Consensus nomenclature for in vivo imaging of reversibly binding radioligands
    Robert B Innis
    National Institute of Mental Health, Molecular Imaging Branch, Bethesda, Maryland, USA
    J Cereb Blood Flow Metab 27:1533-9. 2007
    ..An international group of experts in pharmacokinetic modeling recommends a consensus nomenclature to describe in vivo molecular imaging of reversibly binding radioligands...
  9. pmc Toward optimization of imaging system and lymphatic tracer for near-infrared fluorescent sentinel lymph node mapping in breast cancer
    J Sven D Mieog
    Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands
    Ann Surg Oncol 18:2483-91. 2011
    ..Near-infrared (NIR) fluorescent sentinel lymph node (SLN) mapping in breast cancer requires optimized imaging systems and lymphatic tracers...
  10. ncbi Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate
    Roelf Valkema
    Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    J Nucl Med 46:83S-91S. 2005
    ....
  11. pmc The FLARE intraoperative near-infrared fluorescence imaging system: a first-in-human clinical trial in breast cancer sentinel lymph node mapping
    Susan L Troyan
    Breast Care Center, Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA
    Ann Surg Oncol 16:2943-52. 2009
    ..The FLARE imaging system overcomes this major obstacle...
  12. pmc Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper
    Mette Munk Jensen
    Cluster for Molecular Imaging, University of Copenhagen, Copenhagen, Denmark
    BMC Med Imaging 8:16. 2008
    ..Furthermore, we evaluated the accuracy of tumor volume determined from 18F-fluorodeoxyglucose (18F-FDG) PET...
  13. pmc Imaging CXCR4 expression in human cancer xenografts: evaluation of monocyclam 64Cu-AMD3465
    Ravindra A De Silva
    Russell H Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, Maryland 21231, USA
    J Nucl Med 52:986-93. 2011
    ..Our results show that (64)Cu-AMD3465 is capable of detecting lesions in a CXCR4-dependent fashion, with high target selectivity, and may offer a scaffold for the synthesis of clinically translatable agents...
  14. ncbi Accuracy of [18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism
    Olga T Hardy
    Division of Endocrinology, The Children s Hospital of Philadelphia, 34th Street and Civic Center Boulevard, Philadelphia, Pennsylvania 19104, USA
    J Clin Endocrinol Metab 92:4706-11. 2007
    ..This study evaluated the accuracy of 18F-fluoro-l-dihydroxyphenylalanine ([18F]DOPA) positron emission tomography (PET) scans in diagnosing focal vs. diffuse disease and identifying the location of focal lesions...
  15. ncbi MR-based automatic delineation of volumes of interest in human brain PET images using probability maps
    Claus Svarer
    Neurobiology Research Unit, University Hospital of Copenhagen, Rigshospitalet, N9201, 9 Blegdamsvej, DK 2100 Copenhagen, Denmark
    Neuroimage 24:969-79. 2005
    ..In addition, the method applies well in elderly subjects, even in the presence of pronounced cerebral atrophy...
  16. ncbi 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation
    Shu Hang Ng
    Department of Diagnostic Radiology, Chang Gung Memorial Hospital and Chang Gung University, Taiwan
    J Nucl Med 46:1136-43. 2005
    ..In this prospective study, we evaluated the use of 18F-FDG PET, CT/MRI, and their visual correlation for the identification of primary tumors and cervical nodal metastases of SCC of the oral cavity with histologic correlation...
  17. ncbi FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions
    J Aoki
    Department of Diagnostic Radiology, Gunma University School of Medicine, 3 39 22 Showa machi, Maebashi 371 8511, Japan
    Radiology 219:774-7. 2001
    ..To evaluate the standardized uptake value (SUV) of 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG) at positron emission tomography (PET) in the differentiation of benign from malignant bone lesions...
  18. ncbi Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials
    Lalitha K Shankar
    Cancer Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    J Nucl Med 47:1059-66. 2006
  19. ncbi The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors
    Isis Gayed
    Department of Nuclear Medicine, M D Anderson Cancer Center, University of Texas, Houston, Texas 77030, USA
    J Nucl Med 45:17-21. 2004
    ..Therefore, we compared the roles of (18)F-FDG PET and CT in staging and evaluation of early response to imatinib mesylate therapy in recurrent or metastatic GIST...
  20. pmc In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer
    Kimberly A Lears
    Department of Radiation Oncology, Washington University School of Medicine, St Louis, MO, USA
    J Nucl Med 52:470-7. 2011
    ..6.6]-eicosane-1,8-diamine) (SarAr) chelator to bombesin(7-14), radiolabel the conjugate with (64)Cu, and evaluate in vitro and in vivo...
  21. doi Tracer-cocktail injections for combined pre- and intraoperative multimodal imaging of lymph nodes in a spontaneous mouse prostate tumor model
    Anne C van Leeuwen
    Antoni van Leeuwenhoek Hospital, Division of Diagnostic Oncology, 1066 CX Amsterdam, The NetherlandsAntoni van Leeuwenhoek Hospital, Division of Immunology, 1066 CX Amsterdam, The NetherlandsAntoni van Leeuwenhoek Hospital, Netherlands Cancer Institute, Division of Surgical Oncology, 1066 CX Amsterdam, The Netherlands
    J Biomed Opt 16:016004. 2011
    ..Furthermore, this approach improves fluorescent-based guidance and enables both accurate surgical planning and intraoperative detection, based on a single injection...
  22. ncbi Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography
    J H F Rudd
    Division of Cardiovascular Medicine, University of Cambridge, Addenbrooke s Hospital, Cambridge, UK
    Circulation 105:2708-11. 2002
    ..In this study we tested whether 18FDG-PET imaging can identify inflammation within carotid artery atherosclerotic plaques...
  23. ncbi Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG
    Wei Chen
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA
    J Nucl Med 46:945-52. 2005
    ..We characterized (18)F-FLT PET of brain gliomas and compared (18)F-FLT with (18)F-FDG PET in side-by-side studies of the same patients...
  24. pmc Holmium-166 radioembolization for the treatment of patients with liver metastases: design of the phase I HEPAR trial
    Maarten L J Smits
    Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Heidelberglaan 100, E01, 132, 3584 CX Utrecht, The Netherlands
    J Exp Clin Cancer Res 29:70. 2010
    ..Previous studies have demonstrated the safety of 166Ho-PLLA-MS radioembolization ( 166Ho-RE) in animals. The aim of this phase I trial is to assess the safety and toxicity profile of 166Ho-RE in patients with liver metastases...
  25. ncbi Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis
    M K Gould
    Pulmonary Section 111P, VA Palo Alto Health Care System, 3801 Miranda Ave, Palo Alto, CA 94304, USA
    JAMA 285:914-24. 2001
    ..Focal pulmonary lesions are commonly encountered in clinical practice, and positron emission tomography (PET) with the glucose analog 18-fluorodeoxyglucose (FDG) may be an accurate test for identifying malignant lesions...
  26. doi Standards for PET image acquisition and quantitative data analysis
    Ronald Boellaard
    Department of Nuclear Medicine and PET Research, VU University Medical Center, Amsterdam, The Netherlands
    J Nucl Med 50:11S-20S. 2009
    ..Special attention is given to the rationale underlying certain recommendations and to some of the differences in various guidelines...
  27. doi Effects of image characteristics on performance of tumor delineation methods: a test-retest assessment
    Patsuree Cheebsumon
    Department of Nuclear Medicine and PET Research, VU University Medical Center, Amsterdam, The Netherlands
    J Nucl Med 52:1550-8. 2011
    ..The purpose of this study was to assess test-retest variability of tumor delineation methods, with emphasis on the effects of several image characteristics (e.g., resolution and contrast)...
  28. ncbi Skeletal PET with 18F-fluoride: applying new technology to an old tracer
    Frederick D Grant
    Division of Nuclear Medicine PET, Children s Hospital Boston, Boston, Massachusetts 02115, USA
    J Nucl Med 49:68-78. 2008
    ..With the widespread availability of PET scanners and the improved logistics for the delivery of (18)F radiopharmaceuticals, prior limitations to the routine use of (18)F-fluoride bone imaging have largely been overcome...
  29. ncbi EANM/ESC procedural guidelines for myocardial perfusion imaging in nuclear cardiology
    B Hesse
    Department of Clinical Physiology and Nuclear Medicine, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark
    Eur J Nucl Med Mol Imaging 32:855-97. 2005
    ..imaging of myocardial perfusion and viability are presented in 13 sections covering patient information, radiopharmaceuticals, injected activities and dosimetry, stress tests, imaging protocols and acquisition, quality control and ..
  30. ncbi Stress protocols and tracers
    Milena J Henzlova
    J Nucl Cardiol 13:e80-90. 2006
  31. pmc Cerenkov luminescence imaging of medical isotopes
    Alessandro Ruggiero
    Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Nucl Med 51:1123-30. 2010
    ..Here, we report the use of the inherent optical emissions from the decay of radiopharmaceuticals for Cerenkov luminescence imaging (CLI) of tumors in vivo and correlate the results with those obtained ..
  32. doi Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors
    Lisa Bodei
    Division of Nuclear Medicine, European Institute of Oncology, Via G Ripamonti 435, 20141 Milan, Italy
    Eur J Nucl Med Mol Imaging 35:1847-56. 2008
    ..The kidney is the critical organ and despite renal protection, function loss may become evident years later. The aim of this study was to analyse renal parameters in patients who had undergone dosimetry before PRRT...
  33. ncbi Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine
    Edgar J Rolleman
    Department of Nuclear Medicine, Erasmus Medical Centre, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 30:9-15. 2003
    ..Because Lys75 produced serious hyperkalaemia, it is not suitable for clinical use. LysArg, however, is effective in offering renal protection in PRRT and is safe...
  34. ncbi In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems
    Jered C Garrison
    Harry S Truman Memorial VA Hospital, Columbia, Missouri 65201 5275, USA
    J Nucl Med 48:1327-37. 2007
    ..The study directly compares 64Cu bombesin analogs using the CB-TE2A and DOTA chelation systems in a prostate cancer xenograft SCID (severely compromised immunodeficient) mouse model...
  35. doi Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography
    Klaas P Koopmans
    Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, PO Box 30 001, 9700 RB Groningen, The Netherlands
    J Clin Oncol 26:1489-95. 2008
    ..To evaluate and compare diagnostic sensitivity of positron emission tomography (PET) scanning in carcinoid and islet cell tumor patients with a serotonin and a catecholamine precursor as tracers...
  36. ncbi Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors
    Hanwen Zhang
    Division of Radiological Chemistry, Institute of Nuclear Medicine, Department of Radiology, University Hospital, Basel
    Cancer Res 64:6707-15. 2004
    ....
  37. ncbi Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer
    Ursula Nestle
    Department for Nuclear Medicine, Saarland University Medical Center, Homburg Saar, Germany
    J Nucl Med 46:1342-8. 2005
    ..This investigation compared the gross tumor volumes (GTVs) resulting from 4 methods used for this purpose in a set of clinical cases...
  38. pmc Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET)
    Monica Shokeen
    Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Acc Chem Res 42:832-41. 2009
    ..significant achievements, such as the development of more sensitive imaging instruments and robust, safer radiopharmaceuticals, thereby providing more choices to fit personalized medical needs...
  39. doi Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study
    Shigeto Ueda
    Department of Surgery, National Defense Medical College, 3 2 Namiki, Tokorozawa, Saitama, 359 8513, Japan
    Breast Cancer 18:299-308. 2011
    ....
  40. pmc Transcatheter intraarterial therapies: rationale and overview
    Robert J Lewandowski
    Department of Radiology, Section of Interventional Radiology, Northwestern University Feinberg School of Medicine, Northwestern Memorial Hospital, Robert H Lurie Comprehensive Cancer Center, 676 N St Clair St, Suite 800, Chicago, IL 60611, USA
    Radiology 259:641-57. 2011
    ..As part of the interventional oncology review series, in this article we describe the rationale behind each of these transcatheter therapies and provide a review of the existing medical literature...
  41. pmc 18F-fluromisonidazole PET imaging as a biomarker for the response to 5,6-dimethylxanthenone-4-acetic acid in colorectal xenograft tumors
    Christoph Oehler
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Nucl Med 52:437-44. 2011
    ..The aim of this study was to evaluate (18)F-fluromisonidazole ((18)F-FMISO) PET for monitoring the tumor response to the antivascular compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA; vadimezan)...
  42. pmc Multiplexed PET probes for imaging breast cancer early response to VEGF₁₂₁/rGel treatment
    Min Yang
    Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu 214063, China
    Mol Pharm 8:621-8. 2011
    ..This preclinical study should be helpful in accelerating anticancer drug development and promoting the clinical translation of molecular imaging...
  43. doi MRI-based attenuation correction for whole-body PET/MRI: quantitative evaluation of segmentation- and atlas-based methods
    Matthias Hofmann
    Department of Empirical Inference, Max Planck Institute for Intelligent Systems, Tubingen, Germany
    J Nucl Med 52:1392-9. 2011
    ..We assessed 2 algorithms for whole-body MRI-based AC (MRAC): a basic MR image segmentation algorithm and a method based on atlas registration and pattern recognition (AT&PR)...
  44. doi The next generation of positron emission tomography radiopharmaceuticals in oncology
    Samuel L Rice
    Radiochemistry Service, Department of Radiology and Program in Molecular Pharmacology and Chemistry, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, USA
    Semin Nucl Med 41:265-82. 2011
    ..biological targets, and the most recent preclinical or clinical data of some of the next generation of PET radiopharmaceuticals. This review, which is by no means exhaustive, has been separated into sections related to the PET ..
  45. pmc Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report
    Kazuhiro Namura
    Department of Urology, Yokohama City University Graduate School of Medicine, 3 9 Fukuura kanazawaku Yokohama, 236 0004 Japan
    BMC Cancer 10:667. 2010
    ....
  46. pmc Quantitative evaluation of scintillation camera imaging characteristics of isotopes used in liver radioembolization
    Mattijs Elschot
    Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands
    PLoS ONE 6:e26174. 2011
    ..The aim of this study is to quantitatively evaluate and compare the imaging characteristics of these three isotopes, in order that imaging protocols can be optimized and RE studies with varying isotopes can be compared...
  47. ncbi Comparison of CT- and FDG-PET-defined gross tumor volume in intensity-modulated radiotherapy for head-and-neck cancer
    Arnold C Paulino
    Department of Radiation Oncology, Division of Nuclear Medicine and Molecular Imaging, Emory Clinic and Emory University, Atlanta, GA, USA
    Int J Radiat Oncol Biol Phys 61:1385-92. 2005
    ....
  48. doi Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN)
    Damian Wild
    Division of Radiological Chemistry, University Hospital, Basel, Switzerland
    Cancer Res 71:1009-18. 2011
    ..Furthermore, (213)Bi-DOTA-PESIN has a better safety profile than (213)Bi-AMBA, and represents a possible new approach for use in peptide-receptor radionuclide α-therapy treating recurrent prostate cancer...
  49. doi Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging?
    Stephan Walrand
    Center of Nuclear Medicine, Universite Catholique de Louvain, Brussels, Belgium
    Eur J Nucl Med Mol Imaging 38:S57-68. 2011
    ..The potential imaging capabilities with the radioisotopes (87)Y and (88)Y are also considered. Additional studies required to assess specific unaddressed issues are also identified...
  50. pmc The use of alternative forms of graphical analysis to balance bias and precision in PET images
    Jean Logan
    Medical Department, Brookhaven National Laboratory, Upton, New York 11973, USA
    J Cereb Blood Flow Metab 31:535-46. 2011
    ..The variance of the four estimates can serve as a guide to the reliability of the median estimate. This may provide a general method for the generation of parametric images with little bias and good precision...
  51. ncbi MicroPET imaging of breast cancer using radiolabeled bombesin analogs targeting the gastrin-releasing peptide receptor
    Jesse J Parry
    Department of Radiation Oncology, Washington University School of Medicine, 4511 Forest Park Blvd Suite 411, St Louis, MO 63108, USA
    Breast Cancer Res Treat 101:175-83. 2007
    ..Current radiopharmaceuticals have limited sensitivity for detecting small primary lesions and it has been suggested that novel ..
  52. ncbi Cardiac sympathetic denervation assessed with 123-iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients
    Mark J Boogers
    Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands
    J Am Coll Cardiol 55:2769-77. 2010
    ....
  53. doi Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers
    Anna Imhof
    Institute of Nuclear Medicine, University Hospital, Petersgraben 4, Basel, Switzerland
    J Clin Oncol 29:2416-23. 2011
    ..To investigate response, survival, and safety profile of the somatostatin-based radiopeptide (90)yttrium-labeled tetraazacyclododecane-tetraacetic acid modified Tyr-octreotide ([(90)Y-DOTA]-TOC) in neuroendocrine cancers...
  54. ncbi In vitro and in vivo evaluation of 111In-DTPAGlu-G-CCK8 for cholecystokinin-B receptor imaging
    Luigi Aloj
    Istituto di Biostrutture e Bioimmagini, Consiglio Nazionale delle Ricerche, Naples, Italy
    J Nucl Med 45:485-94. 2004
    Regulatory peptides and their analogs are being extensively investigated as radiopharmaceuticals for cancer imaging and therapy...
  55. ncbi Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations
    N Avril
    Departments of Nuclear Medicine and Gynecology, Technische Universitat Munchen, Munich, Germany
    J Clin Oncol 18:3495-502. 2000
    ..To evaluate the diagnostic value of positron emission tomography (PET) using fluorine-18 fluorodeoxyglucose (FDG) for the diagnosis of primary breast cancer...
  56. doi Cardiac iodine-123 metaiodobenzylguanidine imaging predicts sudden cardiac death independently of left ventricular ejection fraction in patients with chronic heart failure and left ventricular systolic dysfunction: results from a comparative study with si
    Shunsuke Tamaki
    Division of Cardiology, Osaka General Medical Center, Osaka, Japan
    J Am Coll Cardiol 53:426-35. 2009
    ....
  57. pmc Impact of [¹⁸F]FDG PET imaging parameters on automatic tumour delineation: need for improved tumour delineation methodology
    Patsuree Cheebsumon
    Department of Nuclear Medicine and PET Research, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 38:2136-44. 2011
    ..e. reconstruction parameters, noise levels and tumour characteristics, and thereby the need for standardization or inter-institute calibration...
  58. ncbi The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival
    Elizabeth A Kidd
    Department of Radiation Oncology, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Cancer 110:1738-44. 2007
    ....
  59. ncbi Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study
    M Diehl
    Department of Nuclear Medicine, University of Frankfurt Main, Theodor Stern Kai 7, 60590 Frankfurt Main, Germany
    Eur J Nucl Med 28:1671-6. 2001
    ..It is concluded that FDG-PET is a useful method in the staging and follow-up of MTC...
  60. ncbi Reproducibility of 18F-FDG microPET studies in mouse tumor xenografts
    Mangal Dandekar
    Department of Radiology and the Bio X Program, Stanford University School of Medicine, Stanford, California, USA
    J Nucl Med 48:602-7. 2007
    ..However, the reproducibility of serial scans has not been determined. The purpose of this study was to determine the reproducibility of (18)F-FDG small-animal PET studies...
  61. ncbi Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006
    Johannes Czernin
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Clinic Nuclear Medicine, David Geffen School of Medicine, UCLA, Los Angeles, California 90095 6948, USA
    J Nucl Med 48:78S-88S. 2007
    ..From these data, we believe, has emerged reliable evidence in support of the notion that PET/CT offers diagnostic advantages over its individual components for the major cancers...
  62. ncbi Experience with indium-111 and yttrium-90-labeled somatostatin analogs
    I Virgolini
    Department of Nuclear Medicine, University of Vienna, A 1090, Vienna, Austria
    Curr Pharm Des 8:1781-807. 2002
    ..However, an optimal radiopeptide formulation does not yet exist for receptor-targeted radionuclide therapy. Ongoing developments may result in peptides more suitable for this kind of receptor-targeted radionuclide therapy...
  63. ncbi Individual cerebral metabolic deficits in Alzheimer's disease and amnestic mild cognitive impairment: an FDG PET study
    Angelo Del Sole
    Institute of Radiological Sciences, University of Milan, Unit of Nuclear Medicine, Hospital San Paolo, Via Antonio di Rudinì, 8, 20142 Milan, Italy
    Eur J Nucl Med Mol Imaging 35:1357-66. 2008
    ..The purpose of the study was the identification of group and individual subject patterns of cerebral glucose metabolism (CMRGlu) in patients with Alzheimer's disease (AD) and with amnestic mild cognitive impairment (aMCI)...
  64. ncbi Evolving role of positron emission tomography in the management of patients with inflammatory and other benign disorders
    Ghassan El-Haddad
    Division of Nuclear Medicine, Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
    Semin Nucl Med 34:313-29. 2004
    ..With the development and the introduction of several new PET radiotracers, it is expected that PET will secure a major role in the management of patients with inflammatory and other benign disorders...
  65. doi Is pre-therapeutical FDG-PET/CT capable to detect high risk tumor subvolumes responsible for local failure in non-small cell lung cancer?
    Andrij Abramyuk
    OncoRay, Center for Radiation Research in Oncology, TU, Dresden, Germany
    Radiother Oncol 91:399-404. 2009
    ..The aim of this study was to find out whether FDG-PET/CT is capable to predict tumor relapse location in patients with NSCLC, in particular to determine high risk tumors' subvolumes responsible for local failure...
  66. doi Value of 18F-fluoro-L-dopa PET in the preoperative localization of focal lesions in congenital hyperinsulinism
    Carmen Capito
    Departments of Pediatric Surgery, Radiology, Pathology, and Pediatrics, Necker Enfants Malades Hospital, AP HP, 75015 Paris, France
    Radiology 253:216-22. 2009
    ....
  67. doi Computer aided diagnosis system for the Alzheimer's disease based on partial least squares and random forest SPECT image classification
    J Ramirez
    Dept of Signal Theory, Networking and Communications, University of Granada, Periodista Daniel Saucedo Aranda S N, 18071 Granada, Spain
    Neurosci Lett 472:99-103. 2010
    ..7%, and 96.9%, respectively. Moreover, the proposed CAD system outperformed several other recently developed AD CAD systems...
  68. ncbi Clinical use of positron emission tomography in the management of cutaneous melanoma
    Kent P Friedman
    Department of Radiology, Johns Hopkins University Hospital, Baltimore, MD 21287 0817, USA
    Semin Nucl Med 34:242-53. 2004
    ....
  69. ncbi 18F-FDG kinetics and gene expression in giant cell tumors
    Ludwig G Strauss
    Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany
    J Nucl Med 45:1528-35. 2004
    ..18F-FDG kinetics were evaluated by use of compartment and noncompartment models of giant cell tumors. The kinetic data were compared with the gene expression data for a subgroup of patients...
  70. ncbi [18F]FLT-PET in oncology: current status and opportunities
    Lukas B Been
    PET Center, Groningen University Hospital, Groningen, RB, The Netherlands
    Eur J Nucl Med Mol Imaging 31:1659-72. 2004
    ..The opportunities provided by, and the limitations of, [18F]FLT as a proliferation tracer are addressed in this review, and directions are given for further research, taking into account the strong and weak points of the new tracer...
  71. doi The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer
    Maria Picchio
    Department of Nuclear Medicine, San Raffaele Scientific Institute, Milan, Italy
    Eur Urol 59:51-60. 2011
    ..However, no final recommendations have been made on the use of this modality for patient management...
  72. doi The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT
    Mohsen Beheshti
    Department of Nuclear Medicine and Endocrinology, PET CT Center LINZ, St Vincent s Hospital, Seilerstaette 4, 4020, Linz, Austria
    Eur Radiol 19:1425-34. 2009
    ....
  73. ncbi Evaluation of sentinel node biopsy by combined fluorescent and dye method and lymph flow for breast cancer
    Takashi Hojo
    National Cancer Center Hospital, Department of Surgery and Division of Breast Cancer, 5 1 1 Tsukiji Chuo ku, Tokyo, Japan
    Breast 19:210-3. 2010
    ..We compared the combination of radioisotope or dye with a fluorescence compound to analyze lymph flow to identify targets for SNB...
  74. ncbi Cardiac sympathetic degeneration correlates with olfactory function in Parkinson's disease
    Mutsumi Iijima
    Department of Neurology, Tokyo Women s Medical University, Kawada cho Shinjuku, Tokyo, Japan
    Mov Disord 25:1143-9. 2010
    ..The results suggest that the cardiac sympathetic nervous system might degenerate in parallel with the olfactory system in patients with early PD, and that these two systems might degenerate at a different rate of speed in advanced PD...
  75. doi 177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy
    Michael Garkavij
    Department of Oncology, Lund University and Lund University Hospital, Lund, Sweden
    Cancer 116:1084-92. 2010
    ..In commonly used dosimetry methods, planar imaging is used for determination of the residence time, whereas the kidney mass is determined from a computed tomography (CT) scan...
  76. doi Prospective preoperative mediastinal lymph node staging by integrated positron emission tomography-computerised tomography in patients with non-small-cell lung cancer
    Christian Perigaud
    Department of Thoracic and Cardiovascular Surgery, CHU Nantes, l institut du thorax, Nantes, France
    Eur J Cardiothorac Surg 36:731-6. 2009
    ..This study aims to evaluate prospectively the accuracy of preoperative integrated 18-fluoro-2-deoxy-D-glucose positron emission tomography-computerised tomography ((18)FDG PET-CT) for mediastinal lymph node staging...
  77. ncbi Cancer nanotargeted radiopharmaceuticals for tumor imaging and therapy
    Gann Ting
    Center of Nanomedicine and National Institute of Cancer Research, National Health Research Institutes, 4F, 123 2, Section 1, Wan Mei Street, Wen Shan Districts, Taipei, 116, Taiwan, ROC
    Anticancer Res 29:4107-18. 2009
    ..The aim of this article is to provide a brief overview of current status of applications, advantages and up-to-date research and development of nanotargeted radiopharmaceuticals in cancer imaging and therapy.
  78. ncbi Parametric imaging of myocardial blood flow with 15O-water and PET using the basis function method
    Hiroshi Watabe
    Department of Investigative Radiology, National Cardiovascular Center Research Institute, Osaka, Japan
    J Nucl Med 46:1219-24. 2005
    ..The basis function method linearizes the solution of the 1-tissue-compartment model, which results in a computationally much faster method than the conventional nonlinear least-squares fitting method in estimating the parameters...
  79. pmc Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study
    James H F Rudd
    Imaging Science Laboratories, Mount Sinai School of Medicine, New York, NY, USA
    Circ Cardiovasc Imaging 2:107-15. 2009
    ..We also tested the hypotheses that the degree of local arterial inflammation measured by PET is correlated with the extent of systemic inflammation and presence of risk factors for vascular disease...
  80. ncbi Cyclic minigastrin analogues for gastrin receptor scintigraphy with technetium-99m: preclinical evaluation
    Elisabeth von Guggenberg
    Department of Nuclear Medicine, Innsbruck Medical University, Anichstrasse 35, A 6020 Innsbruck, Austria
    J Med Chem 52:4786-93. 2009
    ..i. for both 99mTc-EDDA-HYNIC-cyclo-MG1 and 99mTc-EDDA-HYNIC-cyclo-MG2. In an imaging study with 99mTc-EDDA-HYNIC-cyclo-MG1, the tumor was clearly visualized. The metabolite analysis indicated rapid enzymatic degradation in vivo...
  81. ncbi Tumor targeting by an aptamer
    Brian J Hicke
    NeXstar Pharmaceuticals, Boulder, Colorado, USA
    J Nucl Med 47:668-78. 2006
    ..Aptamers are small oligonucleotides that are selected to bind tightly and specifically to a target molecule. We sought to determine whether aptamers have potential for in vivo delivery of radioisotopes or cytotoxic agents...
  82. ncbi GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting
    Meike Korner
    Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Bern, Bern, Switzerland
    J Nucl Med 48:736-43. 2007
    ..Anticipating a major development of GLP-1 receptor targeting in nuclear medicine, our aim was to evaluate in vitro the GLP-1 receptor expression in a large variety of other tumors and to compare it with that in nonneoplastic tissues...
  83. ncbi Differentiation of recurrent astrocytoma from radiation necrosis: a pilot study with 13N-NH3 PET
    Zhang Xiangsong
    Department of Nuclear Medicine, The First Affiliated Hospital, Sun Yat Sen University, 58 Zhongshan Road II, Guangzhou, 510080, China
    J Neurooncol 82:305-11. 2007
    ..The present study assessed the role of (13)N-NH(3) PET in differentiating recurrent cerebral astrocytoma from radiation necrosis...
  84. pmc The role of PET/CT in detection of gastric cancer recurrence
    Sung Hoon Sim
    Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
    BMC Cancer 9:73. 2009
    ..The purpose of this study is to evaluate the efficacy and usefulness of PET/CT for detecting recurrence of gastric cancer after curative resection...
  85. ncbi Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review
    Hein J Verberne
    Department of Nuclear Medicine, Academic Medical Center, University of Amsterdam, F2 238, PO Box 22700, 1100 DE Amsterdam, The Netherlands
    Eur Heart J 29:1147-59. 2008
    ..To derive a more precise estimate of the prognostic significance of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters [early heart mediastinal ratio (H/M), late H/M, and myocardial washout] in heart failure (HF)...
  86. pmc 64Cu-AMD3100--a novel imaging agent for targeting chemokine receptor CXCR4
    Orit Jacobson
    Positron Emission Tomography Radiochemistry Group, National Institute of Biomedical Imaging and Bioengineering, Bethesda, MD 20892, USA
    Bioorg Med Chem 17:1486-93. 2009
    ..We conclude that (64)Cu-AMD3100 exhibits promise as a potential PET imaging agent for visualization of CXCR4-positive tumors and metastases and might be used to guide and monitor anti-CXCR4 tumor therapy...
  87. ncbi Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy
    Mary K G McStay
    Department of Radiology, Royal Free Hospital, London NW3 2QG, England
    Radiology 237:718-26. 2005
    ....
  88. ncbi Combined 99mTc-ECD SPECT and neuropsychological studies in MCI for the assessment of conversion to AD
    B Borroni
    Department of Neurological Sciences, Neurologic Clinic, University of Brescia, P za Spedali Civili 1, 25100 Brescia, Italy
    Neurobiol Aging 27:24-31. 2006
    ..8%. The pattern of hypoperfusion 99mTc-ECD SPECT and the severity of memory deficits predict the risk of progression to probable AD dementia in MCI subjects...
  89. ncbi Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with 11C-5-hydroxytryptophan positron emission tomography
    H Orlefors
    Department of Medical Sciences Endocrine Oncology, Uppsala University Hospital, UAS, 751 85, Uppsala, Sweden
    Eur J Nucl Med Mol Imaging 33:60-5. 2006
    ....
  90. ncbi Preserved myocardial [123I]metaiodobenzylguanidine uptake in autosomal recessive juvenile parkinsonism: first case report
    Masahiko Suzuki
    Department of Neurology, The Jikei University School of Medicine, Tokyo, Japan
    Mov Disord 20:634-6. 2005
    ..Although the clinical features of AR-JP are sometimes quite similar to those of late-onset idiopathic PD, 123I-MIBG myocardial scintigraphy may be a powerful tool to differentiate PD from other parkinsonian syndromes, including AR-JP...
  91. ncbi Clinical relevance of thyroid fluorodeoxyglucose-whole body positron emission tomography incidentaloma
    Annick Van Den Bruel
    Laboratory and Clinic of Experimental Medicine and Endocrinology, Universitaire Ziekenhuizen Gasthuisberg, B 3000 Leuven, Belgium
    J Clin Endocrinol Metab 87:1517-20. 2002
    ..In conclusion, a small series of consecutive thyroid FDG-PET incidentaloma cases is presented and suggests a high rate of clinically relevant malignancies...
  92. ncbi PET of EGFR antibody distribution in head and neck squamous cell carcinoma models
    Gang Niu
    Molecular Imaging Program at Stanford MIPS, Department of Radiology and Bio X Program, Stanford University School of Medicine, Stanford, California 94305 5484, USA
    J Nucl Med 50:1116-23. 2009
    ....
  93. ncbi The role of coordination chemistry in the development of target-specific radiopharmaceuticals
    Shuang Liu
    Department of Industrial and Physical Pharmacy, School of Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN 47907, USA
    Chem Soc Rev 33:445-61. 2004
    There is a great current interest in developing target-specific radiopharmaceuticals for early detection of diseases and radiotherapy of cancers...
  94. pmc 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo
    Jason P Holland
    Radiochemistry Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Nucl Med 51:1293-300. 2010
    ....
  95. ncbi Improved kinetic stability of DTPA- dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives
    Martin Behe
    Department of Nuclear Medicine, Philipps University of Marburg, Baldingerstrasse, 35043, Marburg, Germany
    Eur J Nucl Med Mol Imaging 30:1140-6. 2003
    ..DTPA- dGlu(1)-minigastrin is preferred to "monofunctional" DTPA-Leu(1)-minigastrin for diagnostic application with (111)In for the in vivo detection of CCK-B receptor-expressing tissues...
  96. doi 123 I-mIBG scintigraphy to predict inducibility of ventricular arrhythmias on cardiac electrophysiology testing: a prospective multicenter pilot study
    Jeroen J Bax
    Leiden University Medical Centre, Albinusdreef 2, Leiden, The Netherlands
    Circ Cardiovasc Imaging 1:131-40. 2008
    ....
  97. ncbi 99mTc-bombesin detects prostate cancer and invasion of pelvic lymph nodes
    Francesco Scopinaro
    Dipartimento di Scienze Radiologiche, Sezione di Medicina Nucleare, Universita La Sapienza, Policlinico Umberto I, Rome, Italy
    Eur J Nucl Med Mol Imaging 30:1378-82. 2003
    ..Our preliminary data encourage further studies on the prostate with 99mTc-BN. If the high sensitivity of 99mTc-BN SPET is confirmed, this method may play an important role in diagnosing and staging prostate cancer...
  98. ncbi Preoperative evaluation of hyperparathyroidism: the role of dual-phase parathyroid scintigraphy and ultrasound imaging
    Aysun Sukan
    Department of Nuclear Medicine, Adana Teaching and Medical Research Center, Baskent University Faculty of Medicine, Dadaloglu Mah, 39 Sokak, No 6, Yuregir, 01250 Adana, Turkey
    Ann Nucl Med 22:123-31. 2008
    ..The aim of this study was to evaluate the efficacy of dual-phase 99mTc-methoxyisobutylnitrile (MIBI) parathyroid scintigraphy (PS) and ultrasound (US) in primary (pHPT) and secondary (sHPT) hyperparathyroidism...
  99. ncbi Correlation between serotonin synthesis and 5-HT1A receptor binding in the living human brain: a combined alpha-[11C]MT and [18F]MPPF positron emission tomography study
    Benicio N Frey
    McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, QC, Canada H3A 2B4
    Neuroimage 42:850-7. 2008
    ..The combination of [(18)F]MPPF and alpha-[(11)C]MT PET offers a means to investigate key determinants of 5-HT neurotransmission under physiological and psychopathological conditions in the human brain in vivo...
  100. pmc Clinical role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in post-operative follow up of gastric cancer: initial results
    Long Sun
    Minnan PET Center and Department of Nuclear Medicine, The First Hospital of Xiamen, Fujian Medical University, Xiamen, Fujian Province, China
    World J Gastroenterol 14:4627-32. 2008
    ..To evaluate the clinical role of (18)F-fluorodeoxyglucose positron emission and computed tomography ((18)F-FDG PET/CT) in detection of gastric cancer recurrence after initial surgical resection...
  101. ncbi Consequences of targeted parathyroidectomy guided by localization studies without intraoperative parathyroid hormone monitoring
    Denise M Carneiro-Pla
    Department of Surgery, Miller School of Medicine, University of Miami, Miami, FL, USA
    J Am Coll Surg 202:715-22. 2006
    ....

Research Grants84

  1. MIBG ANALOGUE RADIOPHARMACEUTICALS
    Ganesan Vaidyanathan; Fiscal Year: 2001
    ..Strategies to augment tumor-to-normal tissue ratios will be investigated. The outcome of this study should help improve the endoradiotherapy of neuroendocrine tumors and possibly of medulloblastoma. ..
  2. Ultrasound Ablation on Bone Cancer Under CT Fluoroscopy
    Everette C Burdette; Fiscal Year: 2010
    ..include radiation therapy, surgery, chemotherapy, hormone therapy, and, recently, therapy using systemic radiopharmaceuticals and biphosphonates;radiotherapy remains the treatment of choice...
  3. RECEPTOR-TARGETED COPPER RADIOPHARMACEUTICALS FOR CANCER IMAGING AND THERAPY
    Carolyn Anderson; Fiscal Year: 2009
    ..have yielded significant discoveries that have contributed to the development of PET and therapeutic radiopharmaceuticals, principally, the labeling of somatostatin analogs with 64Cu (T1/2 = 12.7 h;[unreadable]+ (17...
  4. RECEPTOR-TARGETED COPPER RADIOPHARMACEUTICALS FOR CANCER IMAGING AND THERAPY
    Carolyn J Anderson; Fiscal Year: 2010
    ..have yielded significant discoveries that have contributed to the development of PET and therapeutic radiopharmaceuticals, principally, the labeling of somatostatin analogs with 64Cu (T1/2 = 12.7 h;[unreadable]+ (17...
  5. Development of Novel Fluorinated Amino Acids
    Mark Goodman; Fiscal Year: 2003
    ..Our choice of cyclobutyl and branched nonmetabolized amino acids as suitable radiopharmaceuticals for imaging tumors stems from our preliminary in vitro studies in rat 9L gliosarcoma cells demonstrating ..
  6. Development of Novel Fluorinated Amino Acids
    Mark Goodman; Fiscal Year: 2004
    ..Our choice of cyclobutyl and branched nonmetabolized amino acids as suitable radiopharmaceuticals for imaging tumors stems from our preliminary in vitro studies in rat 9L gliosarcoma cells demonstrating ..
  7. RADIOPHARMACEUTICALS FOR BREAST TUMOR IMAGING & THERAPY
    John Katzenellenbogen; Fiscal Year: 2006
    ..These investigations should lead to substantial advances in the availability of diagnostic imaging gents for ER+ tumors and ER subtype- selective imaging agents, to the evaluation in vivo of radiotherapeutic ER ligands. ..
  8. RADIOPHARMACEUTICALS FOR BREAST TUMOR IMAGING & THERAPY
    John Katzenellenbogen; Fiscal Year: 2005
    ..These investigations should lead to substantial advances in the availability of diagnostic imaging gents for ER+ tumors and ER subtype- selective imaging agents, to the evaluation in vivo of radiotherapeutic ER ligands. ..
  9. RADIOPHARMACEUTICALS FOR BREAST TUMOR IMAGING & THERAPY
    John Katzenellenbogen; Fiscal Year: 2000
    ..These investigations should lead to substantial advances in the availability of diagnostic imaging gents for ER+ tumors and ER subtype- selective imaging agents, to the evaluation in vivo of radiotherapeutic ER ligands. ..
  10. RADIOPHARMACEUTICALS FOR BREAST TUMOR IMAGING & THERAPY
    John Katzenellenbogen; Fiscal Year: 2003
    ..These investigations should lead to substantial advances in the availability of diagnostic imaging gents for ER+ tumors and ER subtype- selective imaging agents, to the evaluation in vivo of radiotherapeutic ER ligands. ..
  11. RADIOPHARMACEUTICALS FOR BREAST TUMOR IMAGING & THERAPY
    John Katzenellenbogen; Fiscal Year: 2001
    ..These investigations should lead to substantial advances in the availability of diagnostic imaging gents for ER+ tumors and ER subtype- selective imaging agents, to the evaluation in vivo of radiotherapeutic ER ligands. ..
  12. RADIOPHARMACEUTICALS FOR BREAST TUMOR IMAGING & THERAPY
    John Katzenellenbogen; Fiscal Year: 1999
    ..These investigations should lead to substantial advances in the availability of diagnostic imaging gents for ER+ tumors and ER subtype- selective imaging agents, to the evaluation in vivo of radiotherapeutic ER ligands. ..
  13. ASTATINE AND IODINE RADIOLABELED MONOCLONAL ANTIBODIES
    Michael Rod Zalutsky; Fiscal Year: 2010
    ..its [211At]astatobenzoyl Mal-D-GEEEK analogue and to evaluate their potential as diagnostic and therapeutic radiopharmaceuticals;2) investigate strategies for improving the Mal- GEEEK reagent for labeling internalizing mAbs including ..
  14. DEVELOPMENT OF PET RADIOPHARMACEUTICALS TARGETING GRPR
    BUCK ROGERS; Fiscal Year: 2009
    ..to evaluate the radiolabeled BN analogs in vivo in mice bearing tumor xenografts as radiopharmaceuticals for PET imaging of GRPR...
  15. DEVELOPMENT OF PET RADIOPHARMACEUTICALS TARGETING GRPR
    Buck E Rogers; Fiscal Year: 2010
    ..to evaluate the radiolabeled BN analogs in vivo in mice bearing tumor xenografts as radiopharmaceuticals for PET imaging of GRPR...
  16. RADIOPHARMACEUTICALS FOR BREAST TUMOR IMAGING & THERAPY
    John Katzenellenbogen; Fiscal Year: 2004
    ..These investigations should lead to substantial advances in the availability of diagnostic imaging gents for ER+ tumors and ER subtype- selective imaging agents, to the evaluation in vivo of radiotherapeutic ER ligands. ..
  17. RADIOPHARMACEUTICALS FOR BREAST TUMOR IMAGING & THERAPY
    John Katzenellenbogen; Fiscal Year: 2002
    ..These investigations should lead to substantial advances in the availability of diagnostic imaging gents for ER+ tumors and ER subtype- selective imaging agents, to the evaluation in vivo of radiotherapeutic ER ligands. ..
  18. Radiopharmaceuticals for Breast Tumor Imaging and Therapy
    John A Katzenellenbogen; Fiscal Year: 2010
    ..The aim of this project is to develop specialized radioactive agents (radiopharmaceuticals) to image this receptor non-invasively and to direct radiotoxic isotopes specifically to receptor-..
  19. Radiopharmaceuticals for Breast Tumor Imaging and Therapy
    John Katzenellenbogen; Fiscal Year: 2009
    ..The aim of this project is to develop specialized radioactive agents (radiopharmaceuticals) to image this receptor non-invasively and to direct radiotoxic isotopes specifically to receptor-..
  20. Radiopharmaceuticals for Breast Tumor Imaging and Therapy
    John Katzenellenbogen; Fiscal Year: 2007
    ..The aim of this project is to develop specialized radioactive agents (radiopharmaceuticals) to image this receptor non-invasively and to direct radiotoxic isotopes specifically to receptor-..
  21. PSMA-based Cancer Imaging Agents
    Martin G Pomper; Fiscal Year: 2010
    ..Although we intend to focus on new, low molecular weight radiopharmaceuticals for PET (Aim 1), we will also develop the good manufacturing practice (GMP) synthesis of the one agent on ..
  22. PSMA-based Cancer Imaging Agents
    Martin Pomper; Fiscal Year: 2009
    ..Although we intend to focus on new, low molecular weight radiopharmaceuticals for PET (Aim 1), we will also develop the good manufacturing practice (GMP) synthesis of the one agent on ..
  23. Phosphinimine Conjugates for Tc(Vll) Stabilization in Labeling Peptides
    Kattesh Katti; Fiscal Year: 2003
    A critical issue in the design and development of radiopharmaceuticals that contain a radiometal is the formation of kinetically inert complexes of the radiometal...
  24. Chemistry of Reactive Intermediates Generated from Benzothiazole Derived Drug Can
    Michael Novak; Fiscal Year: 2009
    ..have been under rapid development as anti-tumor, antimicrobial, and antifungal agents and as radiopharmaceuticals for binding and in vivo imaging of A?-plaques, one of the earliest pathological processes in the ..
  25. VALIDATION OF A KINETIC MODEL FOR RECEPTOR IMAGING
    David Vera; Fiscal Year: 1992
    The proposed studies will expand the kinetic modeling of three receptor- binding radiopharmaceuticals: [99mTc]galactosyl-neoglycoalbumin ([99mTc]NGA), [68Ga]deferoxamine-galactosyl-neoglycoalbumin ([68Ga]Df-NGA), and high-density-[99mTc]-..
  26. DEVELOPMENT OF CANCER IMAGING AGENTS
    Henry VanBrocklin; Fiscal Year: 2000
    ..The applicants have outlined a paradigm to develop unique positron and single photon emitting radiopharmaceuticals using the epidermal growth factor receptor tyrosine kinase (EGFRtk) and breast cancer as model systems...
  27. DEVELOPMENT OF CANCER IMAGING AGENTS
    Henry VanBrocklin; Fiscal Year: 1999
    ..The applicants have outlined a paradigm to develop unique positron and single photon emitting radiopharmaceuticals using the epidermal growth factor receptor tyrosine kinase (EGFRtk) and breast cancer as model systems...
  28. POTENTIAL TUMOR OR ORGAN IMAGING AGENTS
    RAYMOND COUNSELL; Fiscal Year: 1993
    ..its inception in 1965, the long term goals of this project have been to design, synthesize and evaluate new radiopharmaceuticals as potentials organ or tumor-imaging agents...
  29. NUCLEAR DIAGNOSTIC METHODS FOR RENAL DISEASE
    JOHN MC AFEE; Fiscal Year: 1990
    ..New radiopharmaceuticals we plan to develop include (1) analogs of mercaptoacetyltriglycine (MAG3) for chelation with Tc-99m as a ..
  30. PET/CT for Multidimensional Translational Cardiovascular Research
    JOHN CANTY; Fiscal Year: 2009
    ..studies of vascular and myocardial structure coupled with molecular imaging using novel cyclotron generated radiopharmaceuticals developed at the adjacent UB Center for Positron Emission Tomography...
  31. 18F-LABELED BENZAMIDES FOR DOPAMINE-D2 STUDIES USING PET
    Chester Mathis; Fiscal Year: 1991
    ..This research is aimed at developing radiopharmaceuticals which localize in discrete regions of the brain based upon their selective affinity for the postsynaptic ..
  32. MIBG ANALOGUE RADIOPHARMACEUTICALS
    Ganesan Vaidyanathan; Fiscal Year: 2000
    ..Strategies to augment tumor-to-normal tissue ratios will be investigated. The outcome of this study should help improve the endoradiotherapy of neuroendocrine tumors and possibly of medulloblastoma. ..
  33. MIBG ANALOGUE RADIOPHARMACEUTICALS
    Ganesan Vaidyanathan; Fiscal Year: 1999
    ..Strategies to augment tumor-to-normal tissue ratios will be investigated. The outcome of this study should help improve the endoradiotherapy of neuroendocrine tumors and possibly of medulloblastoma. ..
  34. Radiopharmaceuticals based on Cross-bridged Ligands
    Edward Wong; Fiscal Year: 2009
    ..A major challenge in developing radiometal-based radiopharmaceuticals is ensuring metal chelate stability in vivo to avoid decreased contrast and increased radiation doses to ..
  35. Radiopharmaceuticals based on Cross-bridged Ligands
    Edward H Wong; Fiscal Year: 2010
    ..A major challenge in developing radiometal-based radiopharmaceuticals is ensuring metal chelate stability in vivo to avoid decreased contrast and increased radiation doses to ..
  36. LABELING OF OCTREOTIDE WITH POSITRON EMITTERS
    Carolyn Anderson; Fiscal Year: 2003
    ..Although there might be several pathways to investigating mechanisms of cell death by copper radiopharmaceuticals, we will focus on whether differences in dissociation of Cu(II) from macrocyclic chelators in SSTR2 analogs ..
  37. LABELING OF OCTREOTIDE WITH POSITRON EMITTERS
    Carolyn Anderson; Fiscal Year: 2005
    ..Although there might be several pathways to investigating mechanisms of cell death by copper radiopharmaceuticals, we will focus on whether differences in dissociation of Cu(II) from macrocyclic chelators in SSTR2 analogs ..
  38. Correlative Studies for NCI Study#7916: Phase I Clinical Trial of Intravenous FAU
    Patricia LoRusso; Fiscal Year: 2009
    ..Chemotherapeutic compounds, labeled with positron emitting radiopharmaceuticals, allow biodistribution of the chemotherapeutic to be imaged in vivo, as well as determination of its uptake ..
  39. LABELING OF OCTREOTIDE WITH POSITRON EMITTERS
    Carolyn Anderson; Fiscal Year: 2006
    ..Although there might be several pathways to investigating mechanisms of cell death by copper radiopharmaceuticals, we will focus on whether differences in dissociation of Cu(II) from macrocyclic chelators in SSTR2 analogs ..
  40. Radiopharmaceuticals based on Cross-bridged Ligands
    Edward Wong; Fiscal Year: 2007
    ..A major challenge in developing radiometal-based radiopharmaceuticals is ensuring metal chelate stability in vivo to avoid decreased contrast and increased radiation doses to ..
  41. Radiopharmaceuticals based on Cross-bridged Ligands
    Edward Wong; Fiscal Year: 2009
    ..A major challenge in developing radiometal-based radiopharmaceuticals is ensuring metal chelate stability in vivo to avoid decreased contrast and increased radiation doses to ..
  42. Correlative Studies for NCI Study#7916: Phase I Clinical Trial of Intravenous FAU
    Patricia Mucci LoRusso; Fiscal Year: 2010
    ..Chemotherapeutic compounds, labeled with positron emitting radiopharmaceuticals, allow biodistribution of the chemotherapeutic to be imaged in vivo, as well as determination of its uptake ..
  43. LABELING OF OCTREOTIDE WITH POSITRON EMITTERS
    Carolyn Anderson; Fiscal Year: 2004
    ..Although there might be several pathways to investigating mechanisms of cell death by copper radiopharmaceuticals, we will focus on whether differences in dissociation of Cu(II) from macrocyclic chelators in SSTR2 analogs ..
  44. POTENTIAL TUMOR OR ORGAN IMAGING AGENTS
    RAYMOND COUNSELL; Fiscal Year: 1991
    ..its inception in 1965, the long term goals of this project have been to design, synthesize and evaluate new radiopharmaceuticals as potentials organ or tumor-imaging agents...
  45. Expanding F-18 Production for PET/CT
    BRUCE WENDELL WIELAND; Fiscal Year: 2010
    ..However, the demand for 18F radiopharmaceuticals other than FDG has recently been predicted to increase dramatically in the next 2-4 years, expanding the ..
  46. SEROTONIN UPTAKE INHIBITOR LIGANDS FOR PET STUDIES
    Chester Mathis; Fiscal Year: 1990
    ..understanding of the evolution and clinical progression of these diseases when used in concert with other radiopharmaceuticals in PET studies...
  47. BIFUNCTIONAL CHELATING AGENTS IN TUMOR LOCALIZATION
    Claude Meares; Fiscal Year: 2002
    ..antibodies to strongly enhance the tumor localization of chelate-tagged bleomycin analogs and other chelate radiopharmaceuticals, and to investigate the mechanism(s) by which tumor uptake of chelate-tagged bleomycins is increased (by an ..
  48. BIFUNCTIONAL CHELATING AGENTS IN TUMOR LOCALIZATION
    Claude Meares; Fiscal Year: 2001
    ..antibodies to strongly enhance the tumor localization of chelate-tagged bleomycin analogs and other chelate radiopharmaceuticals, and to investigate the mechanism(s) by which tumor uptake of chelate-tagged bleomycins is increased (by an ..
  49. BIFUNCTIONAL CHELATING AGENTS IN TUMOR LOCALIZATION
    Claude Meares; Fiscal Year: 2000
    ..antibodies to strongly enhance the tumor localization of chelate-tagged bleomycin analogs and other chelate radiopharmaceuticals, and to investigate the mechanism(s) by which tumor uptake of chelate-tagged bleomycins is increased (by an ..
  50. BIFUNCTIONAL CHELATING AGENTS IN TUMOR LOCALIZATION
    Claude Meares; Fiscal Year: 1990
    ..antibodies to strongly enhance the tumor localization of chelate-tagged bleomycin analogs and other chelate radiopharmaceuticals, and to investigate the mechanism(s) by which tumor uptake of chelate-tagged bleomycins is increased (by an ..
  51. BIFUNCTIONAL CHELATING AGENTS IN TUMOR LOCALIZATION
    Claude Meares; Fiscal Year: 2003
    ..antibodies to strongly enhance the tumor localization of chelate-tagged bleomycin analogs and other chelate radiopharmaceuticals, and to investigate the mechanism(s) by which tumor uptake of chelate-tagged bleomycins is increased (by an ..
  52. State-of-the-Art PET/CT Instrumentation
    Richard E Carson; Fiscal Year: 2010
    ..The need for combined PET/CT will be of even greater importance in research studies using novel radiopharmaceuticals. The interpretation of the spatial localization of a new tracer, where normal uptake patterns are unknown, ..
  53. Novel Cationic 99mTc Complexes for Heart Imaging
    Shuang Liu; Fiscal Year: 2005
    ..Thus, there is a continuing need for better 99mTc radiopharmaceuticals for myocardial perfusion imaging...
  54. Novel Cationic 99mTc Complexes for Heart Imaging
    Shuang Liu; Fiscal Year: 2006
    ..Thus, there is a continuing need for better 99mTc radiopharmaceuticals for myocardial perfusion imaging...
  55. Beta Imager 2000Z Digital Imaging System
    Jason Lewis; Fiscal Year: 2005
    ..Washington University School of Medicine (WUSM) is a world leader in the concept and design of new radiopharmaceuticals and drugs. Aiding in the screening of new radiopharmaceutieals are two state-of-the-art microPET tomographs...
  56. THERMOSYPHON TARGETRY TO IMPROVE F-18 PET
    BRUCE WIELAND; Fiscal Year: 2006
    ..unreadable] The overall objective of the proposed work is to reduce the cost of accelerator produced F-18 radiopharmaceuticals used in Positron Emission Tomography (PET), a Medicare-reimbursed nuclear medicine metabolic imaging ..
  57. THERMOSYPHON TARGETRY TO IMPROVE F-18 PET
    BRUCE WIELAND; Fiscal Year: 2005
    The overall objective of the proposed work is to reduce the cost of accelerator produced F-18 radiopharmaceuticals used in Positron Emission Tomography (PET), a Medicare-reimbursed nuclear medicine metabolic imaging modality used to ..
  58. Development of GRP Receptor-Avid Radiopharmaceuticals
    Timothy Hoffman; Fiscal Year: 2004
    ..the potential for development of one or more radiolabeled Gastrin Releasing Peptide (GRP) receptor-avid radiopharmaceuticals. We propose that these radiopharmaceuticals will be effective site-directed agents, for the treatment and/..
  59. PET/CT Imaging System
    William J Jagust; Fiscal Year: 2010
    ..A medical cyclotron at LBNL operated by a radiochemistry research group, produces a wide variety of radiopharmaceuticals for human and animal use...
  60. 18F-AV-133, A Novel Radiopharmaceutical for Differential Diagnosis of Dementia
    Franz Hefti; Fiscal Year: 2009
    ..We and others have been developing radiopharmaceuticals that allow detection of A amyloid deposits typical for AD...
  61. Development of GRP Receptor-Avid Radiopharmaceuticals
    Timothy Hoffman; Fiscal Year: 2005
    ..the potential for development of one or more radiolabeled Gastrin Releasing Peptide (GRP) receptor-avid radiopharmaceuticals. We propose that these radiopharmaceuticals will be effective site-directed agents, for the treatment and/..
  62. Development of GRP Receptor-Avid Radiopharmaceuticals
    Timothy Hoffman; Fiscal Year: 2006
    ..the potential for development of one or more radiolabeled Gastrin Releasing Peptide (GRP) receptor-avid radiopharmaceuticals. We propose that these radiopharmaceuticals will be effective site-directed agents, for the treatment and/..
  63. Development of GRP Receptor-Avid Radiopharmaceuticals
    Timothy Hoffman; Fiscal Year: 2003
    ..the potential for development of one or more radiolabeled Gastrin Releasing Peptide (GRP) receptor-avid radiopharmaceuticals. We propose that these radiopharmaceuticals will be effective site-directed agents, for the treatment and/..
  64. A Beta-Sensitive Probe System for Use in Endoscopy
    RAYMOND RAYLMAN; Fiscal Year: 2002
    ..of surgical treatment of cancer utilizing handheld beta-sensitive probes in conjunction with tumor-avid radiopharmaceuticals (such as FDG) have previously been developed...
  65. Intrathecal Cancer Therapy using I131 NaI
    Franklin Wong; Fiscal Year: 2002
    ..On the other hand, the locoregional use of radiopharmaceuticals such as beta-emitters with millimeter ranges may overcome such hurdles...
  66. Pharmaceuticals /Carbon Nanostuctures /Endohedral Metal
    Frank Hagelberg; Fiscal Year: 2006
    ..nanodevices, namely Magnetic Resonance Imaging (MRI) and X-ray Imaging contrast agents as well as radiopharmaceuticals used for diagnostic or therapeutic purposes...
  67. Intrathecal Cancer Therapy using I131 NaI
    Franklin Wong; Fiscal Year: 2001
    ..On the other hand, the locoregional use of radiopharmaceuticals such as beta-emitters with millimeter ranges may overcome such hurdles...
  68. Amyloid Imaging Agents for Positron Emission Tomography
    Chester Mathis; Fiscal Year: 2003
    The proposed research involves the development of radiopharmaceuticals that localize in the brain of Alzheimer's disease (AD) subjects bases upon their selective binding to beta- sheet fibrils such as those found in amyloid-beta protein (..
  69. Amyloid Imaging Agents for Positron Emission Tomography
    Chester Mathis; Fiscal Year: 2001
    The proposed research involves the development of radiopharmaceuticals that localize in the brain of Alzheimer's disease (AD) subjects bases upon their selective binding to beta- sheet fibrils such as those found in amyloid-beta protein (..
  70. RESEARCH TRAINING IN BIOMEDICAL PHYSICS
    EDWARD HOFFMAN; Fiscal Year: 2000
    ..Thesis topics include mathematical modeling of physiological processes, systems for production of radiopharmaceuticals, cryo- electron microscopy and development of database and picture archiving systems in radiology, as well ..
  71. Amyloid Imaging Agents for Positron Emission Tomography
    Chester Mathis; Fiscal Year: 2002
    The proposed research involves the development of radiopharmaceuticals that localize in the brain of Alzheimer's disease (AD) subjects bases upon their selective binding to beta- sheet fibrils such as those found in amyloid-beta protein (..
  72. RESEARCH TRAINING IN BIOMEDICAL PHYSICS
    EDWARD HOFFMAN; Fiscal Year: 1999
    ..Thesis topics include mathematical modeling of physiological processes, systems for production of radiopharmaceuticals, cryo- electron microscopy and development of database and picture archiving systems in radiology, as well ..
  73. RESEARCH TRAINING IN BIOMEDICAL PHYSICS
    EDWARD HOFFMAN; Fiscal Year: 2001
    ..Thesis topics include mathematical modeling of physiological processes, systems for production of radiopharmaceuticals, cryo- electron microscopy and development of database and picture archiving systems in radiology, as well ..
  74. DEVELOPMENT OF NEW RENAL FUNCTION IMAGING AGENTS
    John Babich; Fiscal Year: 1999
    None of the existing radiopharmaceuticals for measuring renal function in humans accurately measures effective renal plasma flow. The two commercially used agents exhibit extraction efficiencies of only .80 and ...